stockportfolio.pro
Alkermes plc (ALKS)
Healthcare · Drug Manufacturers - Specialty & Generic · NasdaqGS
Alkermes plc revenue & earnings — last 10 fiscal years
| Metric | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $745.69M | $903.37M | $1.09B | $1.17B | $1.04B | $1.17B | $1.11B | $1.66B | $1.56B | $1.48B |
| Gross profit | $613.57M | $748.63M | $917.85M | $990.56M | $860.44M | $976.43M | $893.73M | $1.41B | $1.31B | $1.28B |
| Net income | $-208.44M | $-157.94M | $-139.31M | $-196.62M | $-110.86M | $-48.17M | $-158.27M | $355.76M | $367.07M | $241.66M |
| Net margin | -28.0% | -17.5% | -12.7% | -16.8% | -10.7% | -4.1% | -14.2% | 21.4% | 23.6% | 16.4% |
Source: Alkermes plc SEC filings (10-K). 17 years of history available in the interactive view.
Explore 17 years of Alkermes plc financials — interactive
Full income statement, balance sheet and cash flow with CAGR and trend on every row, 48 quarters, valuation ratios, plain-English health checks, and Ask — our SEC-grounded research assistant.
Open the interactive view — freeOr start a 7-day free trial to track ALKS in your portfolio →
About Alkermes plc
Alkermes plc, a biopharmaceutical company, engages in the research, development, and commercialization of pharmaceutical products to address unmet medical needs of patients in therapeutic areas in the United States, Ireland, and internationally. The company has a portfolio of proprietary commercial products for the treatment of opioid dependence, alcohol dependence, schizophrenia, bipolar I, and a pipeline of clinical and preclinical product candidates in development for neurological disorders. Its marketed products include ARISTADA, an intramuscular injectable suspension for the treatment of schizophrenia; ARISTADA INITIO for the treatment of schizophrenia in adults; VIVITROL for the treatment of alcohol and prevention of opioid dependence; LYBALVI, an oral atypical antipsychotic drug candidate for the treatment of adults with schizophrenia and bipolar I disorder; and LUMRYZ, an extended-release oral suspension product for the treatment of cataplexy or EDS in pediatric patients. The company also offers proprietary technology platforms to third parties to enable them to develop, commercialize, and manufacture products. It has collaboration agreements primarily with Janssen Pharmaceutica N.V., Janssen Pharmaceutica Inc, and Janssen Pharmaceutica International. Alkermes plc was founded in 1987 and is headquartered in Dublin, Ireland.
Alkermes plc — frequently asked questions
What is Alkermes plc's revenue?
Alkermes plc (ALKS) reported revenue of $1.48B for fiscal year 2025, down 5.2% from the prior year, according to its SEC filings.
Is Alkermes plc profitable?
Yes. ALKS earned net income of $241.66M in fiscal 2025, a net margin of 16.4%.
What is ALKS's P/E ratio?
Alkermes plc trades at a price-to-earnings ratio of about 49.0 based on the latest data in our nightly-refreshed cache.
How fast is Alkermes plc growing?
ALKS's revenue grew at roughly 7.3% per year over the last five fiscal years (compound annual growth rate), computed from SEC-filed statements.
Where does this data come from?
All figures are computed from Alkermes plc's official SEC filings (10-K and 10-Q), covering 17 years of history, refreshed nightly. stockportfolio.pro does not provide investment advice.